本文選題：慢性淋巴細胞白血病　切入點：BTK抑制劑　出處：《中國實驗血液學(xué)雜志》2017年01期

【摘要】：慢性淋巴細胞白血病(chronic lymphocytic leukemia,CLL)是西方國家最常見的成人白血病,以CD5~+CD19~+CD23~+的B淋巴細胞在外周血、骨髓和淋巴結(jié)中的聚集為特征。在過去的20年里,CLL的治療發(fā)生了一個戲劇性的變化,患者治療后完全緩解率(complete responses,CR)由最初的5%提高到了現(xiàn)在的40%-50%。這一進步歸因于聯(lián)合化學(xué)免疫療法對慢性淋巴細胞白血病患者骨干的治療,尤其近5年來一些新型藥物的爆發(fā)式出現(xiàn),給復(fù)發(fā)/難治患者和細胞遺傳學(xué)異常患者的治療提供了十分有效的方案。本文主要針對已被批準或已用于臨床治療CLL的新型小分子藥物最新研究進展作一綜述,討論的主要藥物包括布魯頓酪氨酸激酶抑制劑(ibrutinib),P13K抑制劑(idelalisib),Syk抑制劑,BCL-2抑制劑等。
[Abstract]:Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in western countries, with B lymphocytes from CD5 ~ CD19 ~ CD23 ~ in peripheral blood. The aggregation of bone marrow and lymph nodes has been characterized by a dramatic change in the treatment of CLL over the past 20 years. After treatment, the complete response rate (CR) increased from the initial 5% to the present 40%. This progress is attributed to the treatment of the backbone of patients with chronic lymphocytic leukemia by combined chemotherapy, especially the explosive appearance of some new drugs in the past five years. It provides a very effective scheme for the treatment of recurrent / refractory patients and patients with cytogenetic abnormalities. This article reviews the latest research progress of new small molecular drugs that have been approved or have been used in clinical treatment of CLL. The main drugs discussed include Bruton tyrosine kinase inhibitor P13K P13K and Syk inhibitor BCL-2.
【作者單位】： 蘭州軍區(qū)蘭州總醫(yī)院全軍血液病中心;
【分類號】：R733.72
，

本文編號：1676445